A5008299243- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Epigenetics and DNA Methylation
- Acute Myeloid Leukemia Research
- Inflammatory Bowel Disease
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Microscopic Colitis
- Histone Deacetylase Inhibitors Research
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Glycosylation and Glycoproteins Research
- Melanoma and MAPK Pathways
- T-cell and B-cell Immunology
- Cancer Treatment and Pharmacology
- Liver Diseases and Immunity
- Neutropenia and Cancer Infections
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Radiopharmaceutical Chemistry and Applications
- Systemic Lupus Erythematosus Research
- Hematopoietic Stem Cell Transplantation
- HIV/AIDS drug development and treatment
Impact Technology Development (United States)
2023
Digital Research Alliance of Canada
2023
Washington University in St. Louis
2022
Astex Pharmaceuticals
2015-2019
Plex Pharmaceuticals (United States)
2019
Prometheus Biosciences (United States)
2013-2014
Prometheus (United States)
2014
Society for Immunotherapy of Cancer
2014
Prometheus Research (United States)
2014
Marymount University
2014
We studied two patients with malignant B-cell lymphoma that manifested resistance to the therapeutic effects of anti-idiotype antibody because emergence subclones changes in their immunoglobulin idiotypes. In both patients, tumor-cell populations arose were unreactive but retained surface immunoglobulin. One had an additional subpopulation tumor cells switched from mu gamma heavy-chain expression. Study genes tumors confirmed subpopulations derived same original clone neoplastic B each...
High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and melanoma (mM) 1998, an era predating targeted therapies immune checkpoint inhibitors. The PROCLAIMSM registry established to collect analyze data patients treated with HD IL-2 the current era. This analysis includes 170 mM 192 mRCC between 2005 2012 survival as July 27, 2015. For mM, complete response (CR) observed 5 %, partial (PR) 10 stable disease (SD) 22 63 % had progressive...
Ninety central venous catheters were inserted into 80 patients undergoing therapy for malignant neoplasms. Bacteremia and fungemia occurred in 18 of 41 treatment courses with acute leukemia nine 55 solid tumors lymphomas. Although gram-negative organisms accounted (33%) cases infection, the majority disseminated infections caused by gram-positive (12 [45%] cases) or fungi (six [22%] cases). Central may be helpful intensive cytotoxic agents, but shift in-spectrum infection to bacteremias...
The immunomodulatory activity of DNA hypomethylating agents (DHAs) suggests they may improve the effectiveness cancer immunotherapies. phase Ib NIBIT-M4 trial tested this hypothesis using next-generation DHA guadecitabine combined with ipilimumab.Patients unresectable stage III/IV melanoma received escalating doses 30, 45, or 60 mg/m2/day subcutaneously on days 1 to 5 every 3 weeks, and ipilimumab mg/kg intravenously day starting week after guadecitabine, for four cycles. Primary endpoints...
BACKGROUND Outcomes for patients with relapsed or refractory acute myeloid leukemia (AML) are poor. Guadecitabine, a next‐generation hypomethylating agent, could be useful in treating such patients. METHODS In this multicenter, open‐label, phase 2 dose‐expansion study, AML from 10 North American medical centers were first randomized (1:1) to receive subcutaneous guadecitabine at 60 90 mg/m on 5 consecutive days each 28‐day cycle (5‐day regimen). Subsequently, another cohort was treated...
<h3>Background and aims</h3> Pilot studies with visilizumab, a humanised monoclonal antibody to CD3, suggest efficacy for corticosteroid-refractory ulcerative colitis (UC). A placebo-controlled trial was warranted. <h3>Methods</h3> randomised, double-blind, study evaluated the of visilizumab induction treatment in 127 patients severely active UC despite ≥5 days intravenous corticosteroids. Patients received placebo or 5 μg/kg intravenously on 1 2. Corticosteroids were tapered according...
Before administration of intensive cytotoxic therapy, 90 central venous catheters were inserted into 80 patients with malignancies. Twenty-seven episodes bacteremia and fungemia occurred during 96 treatment courses. The majority these infections due to gram-positive bacteria (45%) or fungi (22%), although gram-negative organisms accounted for 33%. Catheter occlusion in receiving intravenous phenytoin, but blood products could be infused without difficulty. An increase bacteremias...
Visilizumab is a humanized IgG(2) monoclonal anti-CD3 antibody. We evaluated its safety and dose response in severe intravenous steroid-refractory ulcerative colitis (UC).In all, 104 patients were treated. In Stage I, 73 randomly assigned to receive visilizumab 5, 7.5, 10, or 12.5 microg/kg/day for 2 consecutive days. II, 33 received at the optimal clinical (OCD) of 5 Symptomatic remission defined by modified Truelove-Witts severity index. Clinical Mayo score.The rates symptomatic day 15...
Using isolated idiotype (Id) protein we generated panels of antibodies in two patients with follicular lymphoma, one whom had never received prior chemo-or radiotherapy. Flow cytometry and frozen section tissue staining tumor these monoclonal (mAb) revealed multiple subpopulations within each tumor. Individual mAb stained between 7% 83% surface Ig+ cells the samples. These were overlapping no single antibody recognized all cells. However, combinations seemed to capture total both cases. In...
DNA hypomethylating agents (DHAs) play a well-acknowledged role in potentiating the immunogenicity and immune recognition of neoplastic cells. This immunomodulatory activity DHAs is linked to their ability induce or up-regulate on cells expression variety molecules that crucial host-tumor interactions. To further investigate clinical potential diverse epigenetic compounds when combined with immunotherapeutic strategies, we have now compared tumor properties first generation DHAs, azacytidine...
To correlate treatment responses with numbers and types of "host cell infiltrates," lymphoid tissues from 10 patients low-grade B malignancies were stained before, during, after anti-idiotype therapy a panel monoclonal antibodies applied to frozen sections. Tissue penetration by the was confirmed in five these immunoperoxidase methods. Large phenotypic T helper cells main component infiltrate" most patients. Two showed complete near-complete clinical remission, four others had partial...
Using two colour immunofluorescence with fluorescein isothiocyanate and phycoerythrin labelled monoclonal antibodies, multi-parameter flow cytometry was used to examine the antigenic characteristics of peripheral blood lymphocytes in whole patients ulcerative colitis Crohn's disease who were not taking immunosuppressive drugs. The numbers CD4+ CD8+ remained unchanged so that CD4/CD8 ratio same as normal control subjects. In there many activated T cells (CD3+, CD25+). Although natural killer...
A quantitation method for lymphocyte subsets in immunoper-oxidase-stained frozen tissue sections was compared with flow cytometry 23 cases of non-Hodgkin’s lymphoma. Close correlations were obtained, demonstrating the accuracy technic. Weak intensity fluorescence and fragility tumor cells during fluorescence-activated cell sorter (FACS) analyses most likely explanations a number discrepancies observed. The precise, particularly at low values, where it better than FACS. simpler faster...
We evaluated thiotepa in escalating dose a broad phase I and II study using cryopreserved autologous bone marrow transplantation to assure hematopoietic recovery. Thiotepa was administered intravenously (IV) over two hours daily for three consecutive days followed four by transplantation. The ranged from 60 525 mg/m2 (total dose, 180 1,575 mg/m2). A total of 71 patients with malignant melanoma were treated. Forty-three (61%) had received prior cytotoxic therapy 28 untreated. Sixty-two (87%)...
An approach to perform lymphocyte subset analysis on frozen-thawed whole blood (F/T WB) is described.WB from 24 human immunodeficiency virus type 1 (HIV-1) seropositive individuals and 21 controls was analyzed fresh after frozen storage (with or without dimethyl sulfoxide) at ؊80°C, in liquid nitrogen (LN 2 ), ؊20°C.Analysis of F/T WB utilized 3-color flow cytometry with CD45 right angle light scatter gating.Absolute cell counts were obtained for 30 samples by using staining tubes containing...